. Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Yea J Clin Oncol 2024 Nov 19:JCO2402469. doi: 10.1200/JCO-24-02469.
PMID: 39561312